Inovio Pharma (INO)
$7.74 0.22 (2.93%)
19:59 EDT INO Stock Quote Delayed 20 Minutes
Previous Close $7.74
Market Cap 704.05M
PE Ratio -6.79
Volume (Avg. Vol.) 11.05M
Day's Range 7.24 - 7.94
52-Week Range 1.92 - 19.36
Dividend & Yield N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
- From InvestorPlace
- From the Web
Ino stock has brought its COVID-19 vaccine to trial in record time. But for the stock to move higher, it needs to get the product to market.
By Thomas Niel
Biotech investing is tough. If you have a background in this space, sure, knock yourself out. But if you are an investor looking for solid opportunities, look elsewhere, and avoid INO stock. As the overall market recovers, there are plenty of other screaming buys to consider.
INO stock has moved higher based on Inovio's hunt for a coronavirus vaccine. But this race also makes the pharmaceutical firm a one-dimensional investment.
With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.
INO stock still has some serious upside, thanks to its INO-4800. Inovio's coronavirus vaccine takes the lead and is in preclinical trials.
Inovio could be a bargain using probability analysis. INO stock is cheap if there is a greater than 5% chance its COVID-19 vaccine will be successful.
Inovio has a coronavirus vaccine candidate that has just entered testing, and INO stock speculators are going mad over it.
Once an afterthought in the pharmaceutical space, INO stock suddenly looks interesting amid the coronavirus pandemic. However, it could also be a very temporary tailwind.
Gambling on a single vaccine play is always risky. However, INO stock may have substance given that the coronavirus could get a lot worse.
By David Moadel
Inovio may look promising as a contender in the race to develop a vaccine, but INO stock is still very risky. Here's what to look out for.
The timeline to develop the vaccine seems unrealistic. Further, clinical trials will provide credibility to claims.
Oil prices plunged more than 33% at one point, while stock trading was temporarily halted. Here's what happened in the stock market today.
By Ian Cooper
As the world races for a coronavirus vaccine, Inovio remains one of the top “must own” stocks. If it sees success in human trials and can begin delivery of its vaccine this year, I wouldn’t be shocked to see shares of INO closer to $20 a share.
Inovio Pharmaceuticals continues to rally on COVID-19 vaccine hopes, but overbought conditions and key challenges still make INO stock a risky proposition.
INO stock isn't worth chasing as vaccine development may not be as rewarding as the market seems to believe it is.
Inovio is benefiting from the coronavirus outbreak, but there's plenty of speculation and volatility in this stock too.
INO stock has screamed higher on the possibility of a coronavirus vaccine but the underlying company isn't the most fiscally stable.
Inovio is developing a potential vaccine for the coronavirus. If you can handle the volatility, it may be time to buy INO stock.
Inovio Pharmaceuticals (INO) news for Wednesday concerning a vaccine for the coronavirus from China has INO stock skyrocketing.
From Talk Markets
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader